Lenalidomide Accord

Lenalidomide, the active ingredient in Lenalidomide Accord, is an immunomodulatory drug presented as a tablet for oral use. It is indicated for the treatment of multiple myeloma and myelodysplastic syndromes, particularly in adult patients who have received prior therapy.

GNH USA supplies Lenalidomide Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across all markets.

Lenalidomide is used in hematologic malignancies that involve abnormal plasma cell proliferation or dysplastic bone‑marrow clones. - Multiple Myeloma: improves progression‑free survival and reduces tumor burden in patients with relapsed or refractory disease. - Myelodysplastic Syndromes (deletion 5q): decreases transfusion dependence and improves hematologic parameters in eligible patients.

Lenalidomide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Neutropenia: reduced white blood cell count increasing infection risk. - Fatigue: persistent tiredness affecting daily activities. - Nausea: upset stomach often occurring after dosing. - Diarrhea: loose stools that may lead to dehydration.

Serious or Rare Side Effects: - Venous thromboembolism: blood clots in deep veins or lungs requiring immediate attention. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Secondary primary malignancies: emergence of new cancers during treatment.

When prescribing Lenalidomide, clinicians should observe several safety precautions to minimize risks. - Pregnancy contraindication: Category X; avoid use in pregnant women and ensure effective contraception. - Thrombotic risk: assess patient history and consider prophylactic anticoagulation. - Hematologic monitoring: perform regular complete blood counts to detect cytopenias. - Renal impairment: adjust dose in patients with reduced kidney function. - Drug interaction vigilance: review concomitant medications for CYP3A4 modulators. - Store below 25°C: keep in the original packaging, protect from moisture and light.

Lenalidomide interacts with several medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Thalidomide: combined use increases teratogenic and neuropathic risk. - Strong CYP3A4 inducers (e.g., rifampin): markedly lower lenalidomide plasma levels. - Anticoagulants (e.g., warfarin): may enhance bleeding tendency.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): can raise lenalidomide exposure. - NSAIDs: may exacerbate neutropenia or gastrointestinal irritation. - Live vaccines: immunosuppression may reduce vaccine efficacy and increase infection risk.